Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 4, 1996, Pages 396-404

  Caraco, Yoseph ^a,b   Wilkinson, Grant R ^a   Wood, Alastair J J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DAPSONE; DEBRISOQUINE; DRUG METABOLITE; MEPHENYTOIN; OMEPRAZOLE; PLACEBO;

ADULT; ARTICLE; CAUCASIAN; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; RACE DIFFERENCE;

ADULT; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DAPSONE; DEBRISOQUIN; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENZYME INHIBITORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; MEPHENYTOIN; MIXED FUNCTION OXYGENASES; OMEPRAZOLE;

EID: 0029859728     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90196-4     Document Type: Article

References (50)

1. Peck CC, Temple R, Collins JM. Understanding consequences of concurrent therapies. JAMA 1993;269: 1550-2.
2. Guengerich FP. Catalytic selectivity of human cytochrome P450 enzymes relevance to drug metabolism and toxicity. Toxicol Lett 1994;70:133-8.
3. Miners JO, Veronese ME, Birkett DJ. In vitro approaches for the prediction of human drug metabolism. Ann Rep Med Chem 1994;29:307-16.
4. Miners JO, Veronese ME, Birkett DJ. In vitro approaches for the prediction of human drug metabolism. Ann Rep Med Chem 1994;29:307-16.
5. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
6. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemical: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
7. Lennard MS. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal. Pharmacol Toxicol 1990;67:273-83.
8. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;43:53-76.
9. Fleming CM, Branch RA, Wilkinson GR, Guengerich FP. Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4. Mol Pharmacol 1992; 41:975-80.
10. May DG, Porter J, Wilkinson GR, Branch RA. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin Pharmacol Ther 1994;55:492-500.
11. Kinirons MT, O'Shea D, Downing TE, Fitzwilliam AT, Joellenbeck L, Groopman JD, et al. Absence of correlations among three putative in vivo probes of human cytochrome P450 3A4 activity in young healthy men. Clin Pharmacol Ther 1993;54:621-9.
12. Maton PN. Drug therapy-omeprazole. N Engl J Med 1991;324:965-75.
13. Jensen JC, Gugler R. Inhibition of human liver cytochrome P-450 by omeprazole. Br J Clin Pharmacol 1986;21:328-30.
14. Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism-studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 1985;89:1235-41.
15. Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991;21:195-212.
16. Tucker GT. The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 1994;8(suppl 1):33-8.
17. Andersson T, Miners JO, Veronese M, Tassaneeyakul W, Tassaneeyakul W, Meyer UA, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36:521-30.
18. Chiba K, Kobayashi K, Manabe K, Tani M, Kamotaki T, Ishizaki T. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4-hydroxylation. J Pharmacol Exp Ther 1993;226:52-9.
19. Andersson T, Miners JO, Birkett DJ. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 1994;38:131-7.
20. Andersson T, Miners JO, Veronese ME, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 1994;37:597-604.
21. Caraco Y, Tateishi T, Wood AJJ. Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin Pharmacol Ther 1995;58:62-74.
22. Malcolm SL, Marten TR. Determination of debrisoquine sulphate in plasma by GLC-MS. Analyt Chem 1976;48:807.
23. Kahn GC, Boobis AR, Murray S, Brodie MJ, Davies DS. Assay and characterization of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver. Br J Clin Pharmacol 1982;13:637-45.
24. Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquin oxidation in a white British population. J Med Genet 1980;17:102-5.
25. Wedlund PJ, Aslanian WS, Mcallister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984;36:773-80.
26. May G, Porter JA, Uetrecht JP, Wilkinson GR, Branch RA. The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clin Pharmacol Ther 1990;48:619-27.
27. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-48.
28. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
29. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-8.
30. Halpert RH, Guengerich FP, Bend JR, Correia MA. Contemporary issues in toxicology. Selective inhibitors of cytochrome P450. Toxicol Appl Pharmacol 1994;125:163-75.
31. Andersson T, Cederberg C, Heggelund A, Lundbord P. The pharmacokinetics of single and repeated once-daily doses of 10, 20, and 40 mg omeprazole as enteric coated granules. Toxicol Appl Pharmacol 1994;125: 163-75.
32. Andersson T, Regårdh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2:25-31.
33. Chang M, Tybring G, Dahl ML, Gotharson E, Sagar M, Seensalu R, et al. Interphenotypic differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995;39:511-8.
34. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995;57:662-9.
35. Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4́-hydroxylation recruited from an oriental population. J Pharmacol Exp Ther 1992;262: 1195-202.
36. Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundbord P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal metabolizers of omeprazole. Clin Pharmacol Ther 1990;47:79-85.
37. Caraco Y, Lagerstrom PO, Wood AJJ. Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther 1996;60:157-67.
38. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-97.
39. Bertilsson L, Kalow W. Why are diazepam metabolism and the polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations? Clin Pharmacol Ther 1993;53:608-10.
40. Ishizaki T, Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, et al. Interethnic differences in omeprazole metabolism in two S-mephenytoin hydroxylation phenotypes studies in Caucasians and Chinese. Ther Drug Monit 1994;16:214-5.
41. Jacqz E, Hall SD, Branch RA, Wilkinson GR. Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital. Clin Pharmacol Ther 1986;39:646-53.
42. Chang M, Tybring G, Dahl ML, Gotharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics [in press].
43. Adedoyin A, Prakash C, O'Shea D, Blair IA, Wilkinson GR. Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics 1994;4:27-38.
44. Mitra AK, Thummel KE, Unadkat JD, Slattery JT. Metabolism of dapsone in human liver by cytochrome P450 2E1 [abstract]. ISSX Proc 1994;6:248.
45. Kim RB, Chiba K, Ishizaki T, Wilkinson GR. Chlozoxazone (CZX) 6-hydroxylation in Japanese and Caucasians. Clin Pharmacol Ther 1995;57:217.
46. Noble DW, Bannister J, Lamont M, Anderson T, Scott DB. The effect of oral omeprazole on the disposition of lignocaine. Anaesthesia 1994;49:497-500.
47. Ching MS, Elliott SL, Stead CK, Murdock RT, Devenish-Medres SE, Smallwood RA. Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. Ailment Pharmacol Ther 1991;5:523-31.
48. Blohme I, Idstrum JP, Andersson T. A study of the interaction between omeprazole and cyclosporine in renal transplant patients. Br J Clin Pharmacol 1993; 35:156-60.
49. Soons PA, Van den Berg G, Brummelen PV, Jansen JBMY, Lamers CBHN, Breimer DD. Influence of single and multiple dose omeprazole treatment on nifedipine: pharmacokinetics and effects in healthy subjects. Eur J Clin Pharmacol 1992;42:319-24.
50. Andersson T, Lyndborg P, Regårdh CG. Lack of effect of omeprazole treatment on steady state plasma levels of metoprolol. Eur J Clin Pharmacol 1991;40: 61-5.